Gunderson Capital Management Inc. Purchases 2,448 Shares of Eli Lilly and Company $LLY

Gunderson Capital Management Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 960.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,703 shares of the company’s stock after purchasing an additional 2,448 shares during the period. Gunderson Capital Management Inc.’s holdings in Eli Lilly and Company were worth $2,107,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of LLY. Precedent Wealth Partners LLC boosted its stake in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK lifted its holdings in shares of Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares in the last quarter. Family CFO Inc bought a new position in shares of Eli Lilly and Company during the second quarter valued at $54,000. Duquesne Family Office LLC raised its position in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after buying an additional 32,640 shares during the last quarter. Finally, Corient IA LLC purchased a new position in Eli Lilly and Company in the 1st quarter worth about $570,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO David A. Ricks purchased 1,632 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 2.6%

Shares of LLY stock opened at $833.08 on Friday. The company has a market cap of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.19 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a fifty day moving average price of $742.42 and a 200-day moving average price of $766.36. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the business earned $3.92 earnings per share. Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Leerink Partners reissued a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. HSBC increased their price target on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Finally, Berenberg Bank reiterated a “hold” rating and set a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $948.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.